Oncolytics Biotech to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights
Oncolytics Biotech to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights
Conference call and webcast to take place on Thursday, August 1, 2024, at 4:30 p.m. ET
將於2024年8月1日（星期四）下午4:30（紐約時間）舉行電話會議和網絡直播。
SAN DIEGO, Calif. and CALGARY, Alberta, July 24, 2024 /PRNewswire/ -- Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Thursday, August 1, 2024, at 4:30 p.m. ET to discuss a corporate update and financial results for the second quarter 2024.
加州聖地亞哥和阿爾伯塔省卡爾加里，2024年7月24日/美通社/-- 領先的臨床階段公司腫瘤免疫治療專家Oncolytics Biotech Inc.（納斯達克股票代碼：ONCY，tsx股票代碼：ONC）今天宣佈，將於2024年8月1日（星期四）下午4:30（紐約時間），舉行電話會議和網絡直播，討論2024年第二季度的財務業績和公司更新事宜。
Conference Call & Webcast
Date: Thursday, August 1, 2024
Time: 4:30 p.m. ET
Dial In – North American Toll-Free: (800) 836-8184
Dial In – International: (646) 357-8785
RapidConnect: to join the conference call without operator assistance, please click here
Conference ID (if needed): 34386
Webcast: please click here
電話會議和網絡直播
日期：2024年8月1日（星期四）
時間：東部時間下午4:30
北美免費撥打電話：（800）836-8184。
國際撥打電話：（646）357-8785。
如果不需要操作員協助加入電話會議，請使用RapidConnect，點擊此處。
會議ID（如果需要）：34386。
網絡直播：請點擊此處。
A webcast of the call will also be available on the Investor Relations page of Oncolytics' website, available by clicking here, and will be archived for three months. A dial-in replay will be available for one week and can be accessed by dialing (888) 660-6345 (North America) or (289) 819-1450 (International) and using replay code: 34386#.
電話會議的網絡直播也將在Oncolytics官網的投資者關係頁面提供，點擊此處即可訪問，並將保存三個月。重播將在一週內提供，可通過撥打（888）660-6345（北美）或（289）819-1450（國際）並使用重播代碼：34386＃來訪問。
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
關於Oncolytics Biotech Inc.
Oncolytics是一家臨床階段的生物技術公司，正在開發靜脈注射的免疫治療藥物pelareorep。Pelareorep在轉移性乳腺癌和胰腺癌的兩個隨機2期研究和1,2期研究中，表現出有希望的結果。它通過誘導抗癌免疫反應並通過天然和適應性免疫反應促進炎症性腫瘤表型 - 將“冷”腫瘤變爲“熱” - 以治療多種癌症。
Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid and hematological malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For further information, please visit: or follow the company on social media on LinkedIn and on X @oncolytics.
Pelareorep已經證明可以與多種已批准的腫瘤治療方法協同作用。Oncolytics目前正在進行並計劃進行與Pelareorep在實體瘤和血液惡性腫瘤中的聯合臨床試驗，並向轉移性乳腺癌和胰腺癌的註冊研究邁進，這兩項研究均獲得了FDA的快速通道認證。欲了解更多信息，請訪問公司網站或在社交媒體LinkedIn和X上關注公司@oncolytics。
|
Company Contact Jon Patton Director of IR & Communication [email protected] |
Investor Relations for Oncolytics Timothy McCarthy LifeSci Advisors +1-917-679-9282 [email protected] |
|
公司聯繫方式 Jon Patton IR和溝通主管 [email protected] |
Oncolytics的投資者關係 Timothy McCarthy +1-917-679-9282 LifeSci Advisors +1-917-679-9282 [email protected] |
SOURCE Oncolytics Biotech Inc.
來源：Oncolytics Biotech Inc.